These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Subantimicrobial-dose doxycycline in the treatment of moderate facial acne.
    Author: Toossi P, Farshchian M, Malekzad F, Mohtasham N, Kimyai-Asadi A.
    Journal: J Drugs Dermatol; 2008 Dec; 7(12):1149-52. PubMed ID: 19137768.
    Abstract:
    BACKGROUND: Acne is a common inflammatory skin disorder. Oral antibiotics play a significant clinical role in treating acne. OBJECTIVE: The purpose of this study was to compare the efficacy of doxycycline at antimicrobial and subantimicrobial doses for the treatment of acne. METHODS: A prospective, randomized, double-blind, controlled trial was performed. One hundred patients with moderate facial acne were randomized into 2 treatment groups, one receiving a tablet containing 20 mg of doxycycline to be taken twice daily and the other receiving a tablet containing 100 mg of doxycycline and a matching placebo tablet to be taken twice daily. RESULTS: Subantimicrobial-dose doxycycline administered twice daily for 3 months in patients with moderate inflammatory acne results in significant reduction in the number of total inflammatory lesions. There was an 84% reduction in number of papules and a 90% reduction in number of pustules with treatment. CONCLUSION: Subantimicrobial-dose doxycycline is an effective treatment for patients with moderate acne vulgaris.
    [Abstract] [Full Text] [Related] [New Search]